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Gliclazide reduced oxidative stress, 
inflammation, and bone loss in an 
experimental periodontal disease 
model
Objective: The aim of this study was to evaluate the effects of gliclazide on 
oxidative stress, inflammation, and bone loss in an experimental periodontal 
disease model. Material and Methods: Male albino Wistar rats were divided into 
no ligature, ligature, and ligature with 1, 5, and 10 mg/kg gliclazide groups. 
Maxillae were fixed and scanned using micro-computed tomography to quantify 
linear and bone volume/tissue volume (BV/TV) and volumetric bone loss. 
Histopathological, immunohistochemical and immunofluorescence analyses were 
conducted to examine matrix metalloproteinase-2 (MMP-2), cyclooxygenase 2 
(COX-2), cathepsin K, members of the receptor activator of the nuclear factor 
kappa-Β ligand (RANKL), receptor activator of nuclear factor kappa-Β (RANK), 
osteoprotegerin (OPG) pathway, macrophage migration inhibitory factor (MIF), 
superoxide dismutase-1 (SOD-1), glutathione peroxidase-1 (GPx-1), NFKB p 50 
(Cytoplasm), NFKB p50 NLS (nuclear localization signal), PI3 kinase and AKT 
staining. Myeloperoxidase activity, malondialdehyde and glutathione levels, while 
interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels were 
evaluated by spectroscopic ultraviolet-visible analysis. A quantitative reverse 
transcription polymerase chain reaction was used to quantify the gene expression 
of the nuclear factor kappa B p50 subunit (NF-κB p50), phosphoinositide 3-kinase 
(PI3k), protein kinase B (AKT), and F4/80. Results: Micro-computed tomography 
showed that the 1 mg/kg gliclazide treatment reduced linear bone loss compared 
to the ligature, 5 mg/kg gliclazide, and 10 mg/kg gliclazide treatments. All 
concentrations of gliclazide increased bone volume/tissue volume (BV/TV) 
compared to the ligature group. Treatment with 1 mg/kg gliclazide reduced 
myeloperoxidase activity, malondialdehyde, IL-1β, and TNF-α levels (p≤0.05), 
and resulted in weak staining for COX-2, cathepsin k, MMP-2, RANK, RANKL, 
SOD-1, GPx-1,MIF and PI3k.  In addition, down-regulation of NF-κB p50, PI3k, 
AKT, and F4/80 were observed, and OPG staining was strong after the 1 mg/
kg gliclazide treatment. Conclusions: This treatment decreased neutrophil and 
macrophage migration, decreased the inflammatory response, and decreased 
bone loss in rats with ligature-induced periodontitis.
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Introduction
Periodontitis is a chronic oral infectious disease 
that results from a dysregulated host immune 
response towards microorganisms in the dental 
biofilm.1,2 The relationship between periodontitis and 
other pathological conditions could be established by 
the immunogenic potential of host and/or bacterial 
products that reach the bloodstream and target distant 
organs and systems. Periodontal disease (PD)3 is a 
known risk factor for diabetes mellitus (DM), and 
there is evidence that treatment of PD reduces the 
incidence of inflammation and DM complications.4 In 
turn, DM is a risk factor for periodontitis. A bidirectional 
relationship exists between glycemic control and PD 
severity.5 The most common types of diabetes observed 
in primary care practice are type 1 and type 2. Type 
1 diabetes is an autoimmune disease characterized 
by total destruction of pancreatic beta cells, whereas 
insulin resistance, impaired insulin secretion, and 
inappropriate hepatic glucose secretion characterize 
type 2 diabetes.6 The use of anti-diabetic drugs to 
control type 2 DM has secondary pharmacological 
benefits with regard to inflammatory processes.7,8
Gliclazide is an anti-diabetic medication, a second-
generation sulfonylurea. Sulfonylureas release insulin 
from pancreatic cells and act on insulin-sensitive 
tissues to enhance glucose uptake.9,10 While these 
agents directly stimulate insulin secretion by the β-cell, 
Sulfonylureas have also been shown to have anti-
inflammatory effects.11 Insulin stimulation results in 
the activation of distinct pathways involved in metabolic 
regulation, including the phosphatidylinositol-3-kinase 
(PI3K) cascade.10 Gliclazide has a direct effect on PI3K 
insulin-resistant skeletal muscle to enhance insulin 
signalling.10 The PI3K signaling pathway affects the 
inflammatory process, contributing to increased 
neutrophil survival,12 and the osteoclast differentiation 
pattern.13 PI3K expression is higher in tissue from 
patients with periodontitis than in healthy gingival 
tissue.14
Periodontal bone resorption is induced by 
osteoclasts. Receptor activator of nuclear factor-κB 
ligand (RANKL), its receptor RANK, and a decoy 
receptor osteoprotegerin (OPG) are key molecules 
that regulate osteoclast differentiation, recruitment, 
and function.15 Cathepsin-K is a key protease in the 
degradation process of bone matrix molecules. There 
is a positive correlation between cathepsin-K and 
RANKL levels, suggesting that excess production of 
RANKL resulted in the formation of active osteoclasts 
and led to cathepsin-K production in osteoclasts 
in the periodontium of patients with periodontitis, 
thus contributing to osteoclastic bone resorption.16 
Other important proteases involved in destructive 
periodontal diseases are Matrix metalloproteinases 
(MMPs). MMPs were traditionally thought to degrade 
extracellular matrix components and grouped 
according to their substrate specificity in collagenases, 
gelatinases, stromelysins, matrilysins, and membrane 
type. Because type I collagen represents the bulk 
component of periodontal extracellular matrix, special 
attention has been paid to MMP-2 gelatinases in 
periodontitis.17
Gliclazide also decreased the expression of 
inflammatory markers and endothelial dysfunction in 
patients with type 2 diabetes.18 The inhibitory effect of 
gliclazide on AGE-induced monocyte adhesion involves 
a reduction in EC adhesion molecule expression and 
inhibition of nuclear factor kappaB (NF-kappaB) 
activation.19
The aim of this study was to investigate the roles 
of gliclazide in inflammation, bone loss, and PI3K/AKT 
pathway activation in an experimental PD rat model.
Materials and methods
Animals
Fifty (50) male albino Wistar rats (3 months old, 
180-220 g) were bred and housed under standard 
conditions (12-h light/dark cycle and 22±0.1°C) and 
under compliance with the guidelines approved by the 
Animal Ethics Committee of the Federal University of 
Rio Grande do Norte (UFRN), Brazil (No. 066/2014). 
These guidelines conform to Animal Research N3CRs 
guidelines for Reporting of In Vivo Experiments for 
the handling and care of animals. The rats were given 
ad libitum access to food and water for the duration 
of the study.
Experimental periodontitis model
Anesthesia was induced in the rats by 10% ketamine 
intraperitoneal injection (80 mg/kg; Vetnil, São Paulo, 
SP, Brazil) and 2% xylazine (10 mg/kg; Calmium, São 
Paulo, SP, Brazil). Experimental Periodontal Disease 
(PD) was induced by placement of a sterile nylon 
thread ligature (3-0 polysuture; Dentalcremer LTDA, 
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São Paulo, SP, Brazil) around the crown and adjacent 
to the gingival tissue of the maxillary left second 
molar (L groups). The counterlateral side with no 
ligature served as the control group (no treatment, 
no periodontitis induction-NL group).
Control and treatment groups
Stock solution of gliclazide (GLI) was obtained by 
dissolving 30 mg gliclazide (Servier, Rio de Janeiro, 
RJ, Brazil) in distilled water. Distilled water served as 
the vehicle in the NL and L groups. GLI or vehicle was 
administered by oral gavage (1 mL per rat) 1 h before 
ligature placement (induction of experimental PD), and 
once daily thereafter for 10 days. The animals were 
assigned randomly to the following five groups (n=10 
each): NL, L, L with 1 mg/kg GLI, L with 5 mg/kg GLI, 
and L with 10 mg/kg GLI. Drug doses were selected 
based on those used in humans and in in vivo studies 
examining the effect of gliclazide in rats.20 The animals 
were euthanized 11 days after initial treatment with 
an injection of 80 mg/kg thiopental (0.5 g Thiopentax; 
Cristália, São Paulo, SP, Brazil). The maxillae were 
fixed in 10% buffered formalin for histopathological, 
immunohistochemical (IHC), and immunofluorescent 
morphological analyses. Rat maxillae were fixed in 
10% buffered formalin for 24 h and stored in 70% 
alcohol for micro-computed tomography (micro-CT) 
analysis. Gingival tissues were frozen at -80°C for 
myeloperoxidase, malondialdehyde, glutathione, 
cytokine, and quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) analyses.
Biochemical analyses
After euthanasia, blood samples were collected by 
heart puncture for subsequent biochemical analysis.
Serum was obtained for biochemical analyses 
by centrifuging total blood without anticoagulants 
at 2,500 rpm for 15 min. Glucose and glycated 
hemoglobin (HbA1c) serum levels were determined 
by using standardised diagnostic kits (LABTEST®, São 
Paulo, SP, Brazil) and spectrophotometry (BIO2000 
BIOPLUS, São Paulo, SP, Brazil).
Micro-CT analysis
Rat maxillae were scanned in a micro-CT device 
(model 1172; SkyScan, Kontich, Belgium). The 
micro-CT files were converted to Digital Imaging and 
Communications in Medicine format and imported 
into the Dolphin® software package (Dolphin Imaging, 
Chatsworth, CA, USA) for linear bone loss analysis. The 
maxillae were oriented with the second molar, cement 
enamel was identified in the axial plane, and linear 
bone distances on the sagittal plane were recorded for 
the second mesial molar from the CEJ to the alveolar 
bone crest (ABC). Two additional mesial second molar 
palatal measurements were taken 0.3 mm from the 
middle of the crown.
Bone volume/tissue volume (BV/TV) samples 
were oriented using the DataViewer software package 
(ver. 1.5.2; Bruker, Billerica, MA, USA) for volumetric 
analysis. The maxillae were oriented with the second 
molar CEJs parallel to each other in the sagittal and 
coronal planes. The crowns of the first, second, and 
third molars were visible in the axial plane. After 
orientation, the files were imported into CTAn (ver. 
1.16; Bruker) for volumetric analysis. A 40-slice 
volume set at a threshold of 75 was considered to be 
the region of interest for analysis. Analysis started at 
the slice in which furcation first appeared, proceeding 
apically. BV/TV percentage values were recorded and 
averaged for each group (n≥4/group for all micro-CT 
analyses).
Histopathological analysis
Alveolar bone specimens were harvested, 
fixed in 10% neutral-buffered formalin (24 h), 
and demineralized in 5% nitric acid for 14 days. 
Subsequently, the specimens were dehydrated, 
embedded in paraffin, sectioned along the molars 
in the coronal plane, and stained with hematoxylin 
and eosin. Sections (4 m) were analyzed by light 
microscopy (40× magnification) in the Department 
of Morphology at UFRN.
A histologist scored inflammatory cell influx 
and integrity of the alveolar bone and cementum 
in a single-blind manner. Scores were assigned as 
follows: 0, no or sparse inflammatory cell infiltration, 
restricted to the marginal gingiva, with preservation 
of the alveolar process and cementum; 1, moderate 
inflammatory cell infiltration of the entire gingival insert 
with minor alveolar resorption and intact cementum; 
2, marked inflammatory cell infiltration of the gingiva 
and periodontal ligament with marked degradation 
of the alveolar process and partial destruction of 
the cementum; and 3, marked inflammatory cellular 
infiltration with complete resorption of the alveolar 
process and severe destruction of the cementum.21 The 
Kruskal-Wallis test followed by Dunn’s test were used 
to compare medians (GraphPad Prism 5.0 software, 
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La Jolla, CA, USA). A p-value≤0.05 was considered 
representative of statistical significance.
Immunohistochemical analysis
Maxillae tissue was deparaffinized and rehydrated. 
Gingival and periodontal tissue slices (4 μm) were 
washed with 0.3% Triton X-100 in phosphate buffer, 
quenched with endogenous peroxidase (3% hydrogen 
peroxide), and incubated overnight at 4°C with 
primary antibodies against the following proteins (all 
antibodies 1:400): receptor activator of the NF-κB 
ligand (RANKL), superoxide dismutase-1 (SOD-1), 
receptor activator of NF-κB (RANK), glutathione 
peroxidase-1 (GPx-1), osteoprotegerin (OPG), 
matrix metalloproteinase 2 (MMP-2), cathepsin K, 
and cyclooxygenase-2 (Santa Cruz Biotechnology, 
INTERPRISE, São Paulo, SP, Brazil) and incubated for 
30 min with a streptavidin/horseradish peroxidase-
conjugated secondary antibody (Biocare Medical, 
Concord, CA, USA). Immunostaining was visualized 
using colorimetric detection (Biocare Medical, Dakota, 
USA). The staining status was identified as either 
negative or positive; positive staining was defined as 
the presence of brown chromogen. Staining intensity 
and the proportion of immunopositive cells were 
examined independently by two pathologists by light 
microscopy and recorded. Intensity of staining (IS) 
was graded on a 0 to 2 scale according to the following 
semi-quantitative assessment: 0 = no detectable 
staining, 1 = weak staining; 2 = strong staining.22
Immunofluorescence
Three periodontal tissue sections from each animal 
(n=3/group) were deparaffinized in xylene and washed 
in a series of concentrations of ethanol and Phosphate-
Buffered Saline (PBS) buffer. Antigen retrieval was 
performed by placing the sections in 10 mM sodium 
citrate solution with 0.05% Tween 20 for 40 min at 
95°C. The sections were incubated overnight at 4°C 
with rabbit anti-macrophage migration inhibitory factor 
(MIF) primary antibody (1:100 in 1% normal goat 
serum; Santa Cruz Biotechnology, Miami, USA), NFKB 
P50 (cytoplasm), NFKB p50 NLS (Nuclear localization 
signal), PI3K and AKT. The samples were incubated 
with Alexa Fluor 488-conjugated goat anti-rabbit 
secondary antibodies (1:500 in 1% bovine serum 
albumin) and counterstained with DAPI (Sigma, Miami, 
USA). Fluorescent images were then obtained (laser 
scanning microscope 710, 20X objective; Carl Zeiss, 
Jena, Germany). Tissue reactivity using laser scanning 
was assessed by computerized densitometry analysis 
of the digital images.
Myeloperoxidase assay
The extent of neutrophil accumulation in 
gingival tissue samples was measured by assessing 
myeloperoxidase (MPO) activity. Four samples 
of gingival tissue per group were harvested as 
described above and stored at -80°C until required 
for the assay. Gingival tissue was homogenized in 
hexadecyltrimethylammonium bromide (1:20 wt:vol), 
subjected to two freeze/thaw cycles, and centrifuged 
at 5000 rpm for 20 min. MPO activity (in units of MPO/
milligram of tissue) was determined at 450 nm using 
a previously described colorimetric method.23
Malondialdehyde levels
Malondialdehyde (MDA) levels in gingival tissues 
were measured using a previously described assay.24 
Gingival samples were suspended in 1:5 (wt:vol) 
Tris hydrogen chloride (HCl) buffer and minced with 
scissors for 15 s on an ice-cold plate. The resulting 
suspension was homogenized for 2 min with an 
automatic Potter homogenizer and vortexed, and 
1-methyl-2-phenylindole and 37% HCl were added. 
The vortexed solution was then incubated at 45°C 
for 40 min. Solutions were then cooled on ice and 
centrifuged for 10 min at 15,000 g. Sample absorbance 
was measured at 586 nm (as nanomoles/gram of 
tissue).
Non-protein sulfhydryls assay
Glutathione (GSH) levels in gingival tissues were 
measured as a marker of antioxidant activity.25 Five 
gingival samples were harvested per group and stored 
at -70°C until required for the assay. Gingival tissue 
homogenate (0.25 mL 5% tissue solution prepared 
in 0.02 M Ethylenediamine tetraacetic acid/EDTA) 
was added to 320 µL distilled water and 80 µL 50% 
Trichloroacetic acid/TCA. Samples were centrifuged 
at 3000 rpm and 4°C for 15 min. Then, 400 µL 
supernatant was added to 800 µL 0.4 M Tris buffer (pH 
8.9) and 20 µL 0.01 M 5,5’-dithio-bis-[2-nitrobenzoic 
acid]/DTNB. Sample absorbance was measured at 420 
nm. The results were reported as units of GSH per 
milligram of tissue.
Interleukin-1β and tumor necrosis factor-α 
assay
Gingival tissue samples were stored at -70°C until 
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utilized for the assay.26 Gingival samples (five/group) 
were used to determine levels of interleukin-1β (IL-1β) 
and tumor necrosis factor-α (TNF-α) using an enzyme-
linked immunosorbent assay kit (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s 
guidelines, as previously described.27 All samples 
were within the wavelength range of ultraviolet-visible 
spectrophotometry (absorbance measured at 490 nm).
RNA extraction and qRT-PCR
Total RNA from gingival tissues was extracted 
using the Trizol® reagent (Life Technologies, Los 
Angeles, USA) and chloroform (VETEC, São Paulo, SP, 
Brazil), as previously described.28 RNA was isolated 
and purified using the SV Total RNA Isolation System 
(Promega Corporation, Madison, WI, USA). The RNA 
concentration was determined from the optical density 
at a wavelength of 260 nm (using a unit equivalent 
to 40 μg/mL RNA). After isolation, 0.4 μg total RNA 
was reverse transcribed to cDNA (High-Capacity cDNA 
reverse transcription kit, Thermofisher, Los Angeles, 
USA) in a total volume of 20 μL. The reaction mixture 
was incubated at 42°C for 60 min. The reaction was 
terminated by heating at 70°C for 10 min. The cDNA 
was stored at -80°C until further use.
Gene expression was evaluated by PCR amplification 
using primer pairs based on published sequences from 
Rattus norvegicus. The PCR primer sequences were as 
follows: GAPDH forward AACTTGGCAT CGTGGAAGG, 
reverse GTGGATGCAG GGATGATGTT C; PI3K forward 
CAGGAAAGCA GGAAAAGTGC, reverse CGAAGACCAG 
CTCAATA; AKT forward TCACCTCTGA GACCGACACC, 
reverse ACTGGCTGAG TAGGAGAACT G; NF-κB from 
v-rel avian reticuloendotheliosis viral oncogene 
homolog A (Rela) mRNA forward TCTGCTTCCA 
GGTGACAGTG, reverse ATCTTGAGCT CGGCAGTGTT; 
and F4/80 forward GCCCTTCCAACTCATCATGT, reverse 
AGGGAATCCTTTTGCATGTG.
qRT-PCR was performed using fast SYBR green 
master mix and a Step One Plus thermocycler (both 
from Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s instructions. cDNA 
(2.0 μL of each sample) was added to the 1X PCR 
master mix to make a final volume of 20 μL. PCR 
conditions were as follows: 95°C for 5 min and 40 
cycles of 30 s at 95°C, 30 s at 52–60°C (based on 
the target), and 60 s at 72°C. The quantitative fold 
change relative to the NL group was calculated using 
the comparative ΔΔCt method, where Ct is the cycle 
number at which fluorescence first exceeds the 
threshold. Ct values were obtained for each sample by 
subtracting values for GADPH Ct from the target gene 
Ct value. The specificity of resulting PCR products was 
confirmed by melting curve analysis.
Statistical analysis
Data from the linear and volumetric bone loss 
analyses were represented as averaged values 
for each group±mean standard errors (Figure 1). 
Analysis of variance followed by Bonferroni’s test 
was used to compare the groups. The Kruskal-Wallis 
test followed by Dunn’s test were used to compare 
medians (GraphPad Prism 5.0 software, La Jolla, CA, 
USA). A p-value≤0.05 was considered representative 
of statistical significance.
Analysis/Group Statistical measure
Micro CT Distance CEJ to ABC Mean + standard deviation
% BV/TV Mean + standard deviation
He score Median + Range
Immunofluorescence Mean + standard deviation
Cytokines IL-1 β Mean + standard deviation
TNF-α Mean + standard deviation
MPO Mean + standard deviation
MDA Mean + standard deviation
GSH Mean + standard deviation
RT PCR NFKB p50 Mean + standard deviation
P13K Mean + standard deviation
AKT Mean + standard deviation
F4/80 Mean + standard deviation
Figure 1- Analysis/group and statistical measure (central tendency and variability)
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Results
Biochemical analyses
Analyses were performed to determine the effect 
of GLI on systemic changes. Levels of glucose showed 
increased in L group (176.8 mg/dl) compared with NL 
(115.7 mg/dl). The rats with experimental periodontal 
disease showed low levels of glucose compared to 
the L groups: 1 mg/kg GLI (137.2 mg/dl), 5 mg/kg 
GLI (144.1 mg/dl) and 10 mg/kg GLI (135.7 mg/dl) 
(Table 1).
Glycated hemoglobin (HbA1c)  presented 
percentages within the range of values considered 
normal of 3.85%+0.92%,29 with values of NL (3.5%), 
L (3.8%), 1 mg/kg GLI (3.5%) and 5 mg/kg GLI 
(3.3%), respectively. The values for HbA1c in the 10 
mg/kg GLI were below the reference values of 2.61%, 
p<0.05 (Table 1).
Micro-computed tomography assessment of 
experimental PD
Specimens from all rats treated with GLI (1, 5, 
and 10 mg/kg) showed significantly more linear 
bone loss (Distance CEJ to ABC) compared to the 
NL group (mean 0.4515 ± standard deviation 
0.026 mm; Figure 2C). The group treated with 1 
mg/kg GLI (mean 0.8 ± standard deviation 0.29) 
showed a more dramatic reduction in linear bone 
loss (Distance CEJ to ABC) compared to the L group 
(mean 1.34±standard deviation 0.163 mm, p<0.001), 
and compared with other GLI-treated groups: 5 mg/
kg (mean 1.04±standard deviation 0.32, p<0.001) 
and 10 mg/kg (mean 1.08±standard deviation 
0.47, p<0.001) (Figure 2C). A similar pattern was 
observed volumetrically (Figure 2B). L group and the 
groups treated with GLI (1, 5, and 10 mg/kg) showed 
significantly more bone volume/tissue volume (BV/TV) 
loss compared to the NL group (mean 84.73±standard 
deviation 5.25 mm; Figure 2D). The group treated with 
1 mg/kg GLI (mean 27.5±standard deviation 17.5) 
showed reduced bone volume/tissue volume (BV/TV) 
loss compared to the L group (mean 1.77±standard 
deviation 1.82 mm, p<0.001). The 5 mg/kg (mean 
1.04±standard deviation 0.32, p<0.001) and 10 mg/
kg GLI-treated groups (mean 1.08±standard deviation 
0.47, p<0.001) decreased reduction in bone volume/
tissue volume (BV/TV) loss compared with the L group 
(mean 1.77±standard deviation 1.82 mm, p<0.01 and 
p<0.05, respectively) (Figure 2D).
Histopathological analysis
Histopathological analysis showed that structures of 
the periodontal tissue, marginal gingiva and ligament, 
cementum, and alveolar bone were preserved in the 
NL group (Figure 3A). The L group showed infiltration 
of inflammatory cells in association with destruction 
of the cementum and alveolar process (Figure 3B). 
The median histopathological score for this group 
was 3 (range, 3–3; Figure 3). The group treated with 
10 mg/kg GLI exhibited infiltration of inflammatory 
cells and extensive destruction of the cementum and 
alveolar process, with an average histopathological 
score of 3 (range, 3–3; p>0.05; Figures 3E). 
Histopathology revealed slight cellular infiltration 
restricted to the gingival area, with preserved alveolar 
bone and cementum in the 1 mg/kg GLI and 5 mg/
kg GLI groups. Average scores in these groups were 
1 (range, 1–1; p<0.01) and 3 (range, 2–3; p<0.05), 
respectively (Figures 3C and D).
Immunohistochemical analysis
Periodontal tissue from the L group showed a 
marked strong in immunostaining for MMP-2, RANK, 
RANKL, cathepsin K, SOD-1, and GPx-1 compared 
with that from the NL group (Figures 4, 5). Samples 
from animals treated with 1 mg/kg GLI showed weak 
immunostaining for MMP-2, RANKL, RANK (Figure 4C, 
F, and I, respectively), cathepsin K, SOD-1, and GPx-1 
(Figure 5C, F, and I, respectively), and strong staining 
for OPG (Figure 4L).
Immunofluorescence
MIF immunoreactivity was indicated by strong 
labeling in the periodontal area of samples from the L 
group (Figure 6B). Discrete MIF labeling was observed 
in dentin, periodontium, or alveolar bone in samples 
from the NL group (Figure 6A), and weak, diffuse 
labeling was observed in samples from the 1 mg/kg GLI 
group (Figure 6C). Densitometry analysis confirmed 
significantly decreased MIF immunoreactivity in the 
Groups Glucose (mg/dl) HbA1c (%)
NL 115.7±18.86 3.5±0.1
L 178.8±83.58 3.8±0.3
GLI 1 mg/kg 137.2±34.37 3.5±0.4
Gli5 5 mg/kg 144.1±22.5 3.3±0.2 
Gli 10 mg/kg 135.7±40.50 2.6±0.09*
*p<0.05, (L compared among NL and GLI treatments)
Table 1- Determination of the glucose and HbA1c. Biochemistry 
of periodontal disease experimental model
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1 mg/kg GLI group relative to the L group (p<0.001; 
Figure 6D).
Densitometry analysis confirmed significantly 
increased NFKB p50 (cytoplasm) immunoreactivity 
relative NFKB p50 (Nuclear) in the L group (p<0.05; 
Figure 7). PI3K immunoreactivity was indicated by 
strong labeling in the periodontal area of samples 
from the L group (Figure 7). Discrete PI3K labeling 
was observed in dentin, in samples from the NL group 
(Figure 7), and weak, diffuse labeling was observed 
in samples from the 1 mg/kg GLI group (p<0.05; 
Figure 7).
Oxidative stress, inflammation, and gene 
expression analysis
Analysis of gingival tissue samples showed 
increased MDA levels in the L group compared to the 
NL group (p<0.001). All GLI-treated groups showed 
reduced MDA levels compared with the L group (1 and 
5 mg/kg GLI, p<0.001; 10 mg/kg GLI, p≤0.05; Figure 
8A). GSH levels did not differ significantly from those 
in the L group (Figure 8C). GLI at a dose of 1 mg/kg 
Figure 2- Radiographic evaluation after gliclazide (GLI) treatment and induction of experimental periodontitis. (A) Representative sagittal 
2D and 3D micro-CT images from the no ligature (NL), ligature (L), and GLI 1, 5, and 10 mg/kg groups. (B) Representative sagittal 2D and 
3D micro-CT images from the NL, L, and GLI 1, 5, and 10 mg/kg groups. (C) Graph representing linear bone loss in the area of the mesial 
second molar. Distance (in millimeters) from the cementoenamel junction to the alveolar bone crest. Data are mean±standard area of the 
mean. *p<0.05, *p<0.01, ***p<0.001 (n≥3 for all groups/time points). (D) Graph representing the bone volume/total volume percentage in 
the area below the second molar bifurcation. Data are mean±standard area of the mean. *p<0.05, *p<0.01, ***p<0.001 (n≥3 for all groups/
timepoints). Analysis of variance followed by Bonferroni’s test
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prevented the increase of MPO activity (p≤0.05, Figure 
8B) and IL-1β and TNF-α content (both p<0.05; Figure 
9A and B) induced by ligature placement in gingival 
tissue, whereas the other doses analyzed showed 
no significant effect. Animals treated with 1 mg/kg 
GLI showed reduced gene expression levels of NF-κB 
p50, PI3K, AKT (all p<0.05), and F4/80 (p<0.001) 
compared with the L group (Figure 10A–D).
Figure 3- Histological analysis of maxillae from rats with periodontal disease. (A) Normal periodontium (no ligature group) showing alveolar 
bone integrity, absence of or only discrete cellular infiltration, and preserved alveolar bone. (B) Periodontium from a rat with periodontitis 
(ligature group) showing alveolar bone and cementum resorption (discontinuous cementum) and accentuated inflammatory cell infiltration. 
(C) Periodontium from a rat with periodontitis treated with 1 mg/kg gliclazide (GLI) showing reduced inflammation and decreased alveolar 
bone loss. (D) Periodontium from a rat treated with 5 mg/kg gliclazide showing moderate cellular infiltration. (E) Periodontium from a rat 
treated with 10 mg/kg gliclazide  showing no reduced inflammation and increased experimental PD. PL, periodontal ligament; D, dentin; 
AB, alveolar bone; C, cementum; a, inflammatory process; b, bone loss; c, resorption of cementum; d decreased inflammation process. 
Sections were stained with hematoxylin and eosin. Original magnification, 40×. Histopathological scores. *p<0.05, **p<0.01, ***p<0.001
Figure 4- Photomicrographs of periodontal tissue from rats with periodontal disease treated with 1 mg/kg gliclazide (GLI) and control 
groups (no ligature and ligature), showing immunoreactivity to MMP-2, RANK, RANKL, and OPG. (A, D, G, J) Rats with no ligature. (B, E, 
H, K) Rats with ligature. (C, F, I, L) Rats with ligature treated with 1 mg/kg GLI. Arrow indicates high or moderate labeling in inflammatory 
cells in periodontal ligament or alveolar bone. Asterisk and arrow indicates mild labeling in the periodontal ligament. Triangle and arrow 
indicate high labeling of osteoclasts. Asterisk indicates mild labeling in the periodontal ligament or alveolar bone. Images are shown at 
40× magnification
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Figure 5- Photomicrographs of maxillary periodontal tissue from rats with periodontal disease treated with 1 mg/kg gliclazide (GLI) and 
control groups (no ligature and ligature), showing immunoreactivity to cathepsin (CAT), superoxide dismutase-1 (SOD-1) and glutathione 
peroxidase-1 (GPx-1). (A, D, G) Rats with no ligature. (B, E, H) Rats with ligature. (C, F, I) Rats with ligature treated with 1 mg/kg GLI. 
Arrow indicates high or moderate labeling in the periodontal ligament or alveolar bone. Asterisk indicates mild labeling in the periodontal 
ligament or alveolar bone. Triangle indicates intense labeling in alveolar bone. Images are shown at 40× magnification
Figure 6- Gliclazide (GLI) modulates macrophage migration inhibitory factor (MIF) expression. Representative confocal photomicrographs 
of MIF immunoreactivity in periodontal specimens from each group (green) with DAPI nuclear counterstaining (blue). (A) Sample from the 
no ligature group showing discrete MIF labeling in dentin (d), periodontium (p), or alveolar bone (ab); (B) Sample from the ligature group 
shows strong labeling (red arrows) in the periodontal area. (C) Sample from the 1 mg/kg GLI group showing diffuse, weak MIF labeling (red 
star). Scale bar 50 µm, 200× magnification. (D) Densitometry analysis confirmed significantly decreased MIF immunoreactivity in the 1 mg/
kg GLI group, which was blocked in the ligature group. Five immunofluorescence sections from each animal (n=3/group) were analyzed. 
***p<0.001, Kruskal–Wallis test followed by Dunn’s test
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Discussion
Gliclazide at a dose of 1 mg/kg led to significantly 
reduced oxidative stress, inflammation, and bone 
loss, which is in agreement with the results of other 
studies.30-32 GLI-treated rats showed decreased MDA 
levels compared to untreated rats.
Moreover, animals treated with 1 mg/kg gliclazide 
showed weak immunostaining for SOD-1 and GPx-
1 in this study. According to Liu, et al.33 (2014), 
higher SOD levels in patients with periodontitis can 
be explained by the increased stimulation of SOD 
production to protect against biological superoxide 
generation in periodontal inflammation. Gliclazide 
presented antioxidant activity because it showed free 
radical scavenging properties. This property is due to 
the presence of a single aminoazabicyclooctane ring 
present in the sulfonylureas.34
Toxic reactive oxygen metabolites may also 
initiate and/or amplify inflammation via the up-
regulation of several different genes involved in 
inflammatory response, including NF-κB.35 NF-κB 
is a ubiquitous transcription factor and pleiotropic 
regulator of numerous genes involved in immune 
and inflammatory responses. Activation of NF-κB 
amplifies the inflammatory response by up-regulating 
the production of pro-inflammatory cytokines.36 We 
found down-regulation of NF-κB, reduced IL-1β and 
TNF-α levels in the group treated with 1 mg/kg GLI. A 
high concentration of NFKB p50 NLS after treatment 
group with 1 mg/kg GLI was found in the leucocytes 
nucleus; however, the high concentration of NFKB p50 
in the ligature group was found in leucocyte cytoplasm, 
indicating translocation and activity of proteins. These 
cytokines have been implicated in MMP and cathepsin 
Figure 7- Gliclazide (GLI) modulates NFKB P50 (Cytoplasm), NFKB P50 (Nuclear), AKT, PI3K immunoreactivity in periodontal specimens 
from each group (green) with DAPI nuclear counterstaining (blue). Densitometry analysis confirmed significantly increased NFKB p50 
(cytoplasm) immunoreactivity relative NFKB p50 (Nuclear) in the L group (p<0.05). Representative confocal photomicrographs of PI3K 
immunoreactivity was indicated by strong labeling in the periodontal area of samples from the L group. Discrete Pi3K labeling was 
observed in alveolar bone in samples from the NL group  and weak, diffuse labeling was observed in samples from the 1 mg/kg GLI group, 
p<0.05. Asterisks: Dental tissue; Arrows (red): Cells. Scale bar 50 µm, 200× magnification. Five immunofluorescence sections from each 
animal (n=3/group) were analyzed. ***p<0.001, Kruskal-Wallis test followed by Dunn’s test
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K activation. Osteoclasts secrete cathepsin K to break 
down collagen, the major component of the non-
mineral protein matrix of the bone.37
The RANKL/RANK/OPG signaling pathway is 
implicated in bone resorption through its key function 
in osteoclast differentiation and activation, as well as 
in inflammatory response. This central element of 
osteoimmunology has been suggested to be disturbed 
in several diseases, including periodontitis, as it is a 
predisposing factor for this disease.15 Experimental 
periodontitis studies have shown that cytokines like 
IL-1 and TNF-alpha induce osteoclastogenesis via the 
RANKLRANK-OPG pathway.15
The periodontal tissues from, 1 mg/kg GLI group 
showed weak immunostaining for MMP-2, RANKL and 
cathepsin K, as well as less tissue damage and strong 
OPG immunostaining. This group also showed weak 
immunostaining for RANKL and strong immunostaining 
for OPG. The tissues from 1 mg/kg and 5 mg/kg GLI 
groups revealed the presence of mild cellular infiltrate 
restricted to the gingival area with preserved alveolar 
bone and cementum.
Our data showed that the best results related to 
bone loss were found when gliclazide administration at 
the lower doses of 1 mg/kg translates the drug dosage 
from animal to human dose,20 as the therapeutic 
dose of gliclazide in humans occurs in a range of 30 
mg-120 mg/day. We find that the dose of 10 mg/
Figure 8- Levels of (A) MPO, (B) MDA, and (C) GSH in gingival tissue in the no ligature, ligature, and 1, 5, and 10 mg/kg gliclazide groups. 
*p<0.05, **p<0.01
Figure 9- Levels of (A) IL-1β and (B) TNF-α in gingival tissue in the no ligature, ligature, and 1, 5, and 10 mg/kg gliclazide groups. *p<0.05, 
**p<0.01
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kg in animals is close to the maximum therapeutic 
dose in humans (approximately 120 mg/day, while 
the dose of 5 mg is equivalent to 60 mg/day and 1 
mg is equivalent to 12 mg/day, below the therapeutic 
dose). The related biochemical data showed that 
animals with periodontal disease tend to have an 
increase in glucose levels. The fasting glycemia data 
may present different confounding variables; among 
them, the increase in glycemia can vary due to the 
stress during the manipulation process of the animals, 
which does not necessarily refer to periodontal disease 
or hypoglycemic effect. Data regarding glycated 
hemoglobin were considered more reliable data and 
presented a significant percentage reduction in the 
animals treated with gliclazide at a dose of 10 mg/
kg, suggesting a hypoglycemic effect at this dose and 
increased bone loss in periodontal disease. Another 
study showed than metformin significantly activated 
AMPK in dose- and time-dependent manners, and 
induced endothelial nitric oxide synthase (eNOS) and 
bone morphogenetic protein-2 (BMP-2) expressions.38
A reduction in PI3K/AKT and NFKB p50 levels was 
observed in rats treated with 1 mg/kg GLI in this study. 
This reduced pathway activation resulted in a lower 
neutrophil survivability, as confirmed by the reduced 
MPO activity. Gliclazide seems to dysregulate the PI3K/
AKT pathway, thereby reducing neutrophil survivability. 
Early activation of the PI3K/AKT pathway is a major 
step in the inhibition of apoptosis in Anaplasma 
phagocytophilum-infected neutrophils,12 and the role 
of the NFKB and PI3K pathways in neutrophil apoptosis 
inhibition in periodontal inflammation has been 
demonstrated.14 Treatment with 1 mg/kg GLI resulted 
in a more dramatic reduction in bone loss compared 
with the other gliclazide treatments.
The F4/80 glycoprotein is a member of the EGF-
transmembrane 7 family and has been established as a 
specific cell-surface marker for murine macrophages.39 
We observed reduced F4/80 gene expression in the 
group treated with 1 mg/kg GLI in this study, which 
was corroborated by the MIF immunofluorescence 
assay. In the context of PD, MIF has a role in controlling 
bacterial growth, but it more significantly contributes 
to the progression of bone loss by directly affecting 
osteoclast differentiation and activity.13
High doses of gliclazide (e.g., 10 mg/kg) activate 
the PI3K/AKT pathway and increase periodontal bone 
loss. Some cytokines activate the PI3K/AKT pathway, 
leading to osteoclastogenesis.40 An increase in the 
inflammatory cytokine IL-1β was observed in the 10 
mg/kg GLI group. IL-1 has been reported to stimulate 
osteoclastogenesis through two parallel events: direct 
Figure 10- Effects of gliclazide (GLI) on (A) NF-κB p50, (B) PI3K, (C) AKT, and (D) F4/80 mRNA expression in gingival tissue from rats 
without periodontal disease (no ligature) and those with periodontal disease (ligature and 1 mg/kg GLI groups). The expression of NF-κB 
p50, PI3K, AKT, and F4/80 mRNA was decreased in the 1 mg/kg GLI (p<0.05 and p<0.001) and no ligature (p<0.001) groups. Analysis of 
variance followed by Bonferroni’s test (n=5 animals/group)
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enhancement of RANKL expression and suppression 
of OPG expression.40
Conclusion
We conclude that the use of GLI at a 1-mg/kg dose 
in rats reduces the formation of lipid peroxidation 
products, prevents PI3k signaling, and decreases 
IL-1β and TNF-α levels, which in turn reduce 
MMP-2, cathepsin K, and RANKL levels. Reduced 
gene expression of PI3K/AKT pathway genes was 
observed together with lower neutrophils infiltration, 
accompanied by lower neutrophil survivability and 
reduced migration of macrophages (MIF), which may 
have contributed to the reduction in linear bone loss.
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